18 Nov 2020 | All | Samsung Bioepis, Biogen | Samsung Bioepis and Biogen announce the FDA has accepted for review the BLA for SB11 (proposed ranibizumab biosimilar).

12 Nov 2020 | All | Samsung Bioepis | Samsung Bioepis announces one-year results from Ph III study of SB...

November 16, 2020

Significant biosimilar activities this week include:

  • 05 Nov 20: Formycon announced its BLA resubmission strategy for FYB201 (proposed ranibizumab biosimilar) has been adjusted. The approval will now be requested directly for a large commercial scale, which Formycon...

Significant biosimilar activities this week include:

  • 22 Oct 20: Ph III clinical trials of FYB202 (proposed ustekinumab biosimilar developed by Formycon and Bioeq) commenced recruiting in Poland
     

  • 26 Oct 20: Samsung Bioepis announced results from two post-mar...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags